Invivo
Financials
Estimates*
NOK | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Revenues | - | <1m | - | 4.2m | 7.1m |
% growth | - | - | - | - | 69 % |
Profit | (<1m) | <1m | (<1m) | (1.1m) | (1.8m) |
% profit margin | - | 16 % | - | (27 %) | (25 %) |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€2.5m | Grant | ||
Total Funding | AUD4.3m |
Related Content
Recent News about Invivo
EditInvivo.io is a pioneering startup operating in the healthcare technology sector, specifically focusing on bladder function. The company has developed a unique, patented technology that provides continuous pressure monitoring of the bladder. This technology is designed to aid in the diagnosis and treatment of urinary dysfunctions, such as Benign Prostatic Hyperplasia and voiding problems in children.
The company's innovative product is an all-in-one solution that includes a less than 1mm MEMS pressure sensor attached to a wire and an external patch. The sensor is inserted into the bladder via the suprapubic technique, and the patch, which contains electronics for data storage and transfer, is attached to the skin. This allows for high-resolution, accurate, and realistic bladder pressure data to be sent continuously to the cloud for analysis.
Invivo.io's business model is based on providing this unique technology to healthcare providers and patients. The company generates revenue by selling the sensor and patch system, and potentially through subscription-based access to the cloud-based data analysis.
The market for Invivo.io's technology is vast, given the number of people suffering from urinary dysfunction. The company's unique, patented technology positions it well to capture a significant share of this market.
Keywords: Healthcare technology, bladder function, urinary dysfunction, continuous pressure monitoring, MEMS pressure sensor, cloud-based data analysis, patented technology, suprapubic technique, Benign Prostatic Hyperplasia, voiding problems.